期刊文献+

PU/ST/SA复合微球的制备及血液相容性研究 被引量:3

Preparation of PU/ST/SA Complex Microspheres and the Performance of Hemocompatibility
下载PDF
导出
摘要 采用预聚-扩链-中和-分散法合成PU水溶液,将PU、ST、SA溶液按质量比1:1:1、1:1:2、1:1:3进行复合,通过凝聚相分离法制备复合微球。由红外光谱分析样品的化学结构,发现PU与ST和SA之间通过氢键作用复合;由SEM观测微球表面及剖面的形态结构,发现复合微球平均粒径约为2-3mm,表面光滑且内部有很多均匀致密的管状孔隙,适合用作药物释放载体材料;血液相容性测试结果表明,复合微球的动态凝血时间、溶血率以及血小板消耗率均达到了与血液接触材料的国家标准,说明PU/ST/SA复合微球具有良好的血液相容性。 The study was aimed at obtaining favourable PU/ST/SA complex microspheres for drug controlled delivery system. First PU anionic solution was synthesized by the prepotymeization, chain-extension, neutralization, dispersion method. Subsequently PU solution and ST, SA solutions were completely mixed with different quality rate (1 : 1 : 1,1 : 1 : 2,1 : 1 : 3), which was trickled to shape complex microspheres. FTIR results show that they make interaction through hydrogen bond. SEM results show that the average diameter of the completely microspheres is about 2-3mm and they are smooth sphericity, the surfaces are provided with porosity. It can be used as carrier materials for drug delivery. Hemocompatibility test results show that PU/ST/SA complex microspheres have good hemocompatibility.
出处 《材料导报》 EI CAS CSCD 北大核心 2011年第4期30-32,36,共4页 Materials Reports
基金 国家大学生创新性实验计划项目(091061347) 中央高校基本科研业务费专项资金(SWJTU09CX0622010ZT09) 四川省应用基础研究基金(07JY029-065)
关键词 聚氨酯 淀粉 海藻酸钠 血液相容性 polyurethane(PU), starch(ST), sodium alginate(SA), hemocompatibility
  • 相关文献

参考文献5

二级参考文献21

  • 1[2]Xue YL, Gao J, Xi Z, et al. Microencapsulated bovine chromaffin cell xenografts into hemiparkinsonian rats: a drug-induced rotational behavior and histological changes analysis. Artif Organs 2001; 25 (2): 131 - 5 被引量:1
  • 2[4]Eaton MJ, Martinez M, Karmally S, et al. Initial characterization of the transplant of immortalized chromaffin cells for the attenuation of chronic neuropathic pain. Cell Transplant 2000; 9 (5): 637 - 56 被引量:1
  • 3[8]Winnie AP, Pappas GD, Das Gupta TK, et al. Subarachnoid adrenal medullary transplants for terminal cancer pain. Anesthesiology 1993; 79:644 - 53 被引量:1
  • 4[9]Aebischer P, Buchser E, Joseph JM, et al. Transplantation in humans of encapsulated xenogeneic cells without immunosuppression. A preliminary report. Transplantation 1994; 58:1275 - 7 被引量:1
  • 5[10]Buchser E, Goddard M, Heyd B, et al. Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience. Anesthesiology 1996; 85 (5):1005 - 12 被引量:1
  • 6Ispas-Szabo.P,Ravenelle.F Structure-properties relationship in cross-linked high-amylose starch for use in controlled drug release.Carbohydrate Research,1999; (323):163-175. 被引量:1
  • 7Te Wierik G,Henk P,Eissens,Anko C,et al.A new generation of starch products as excipient in pharmaceutical tablets.II.High surface area retrograded pregelatinized potato starch products in sustained-release tablets.Journal of control.Release.1997,(45):25-33. 被引量:1
  • 8Clausen AE,Bemkop-Schnurch A.Direct compressible polymethacrylic acid-starch compositions for site-specific drug delivery.Journal of Controlled Release.2001; (75):91-102. 被引量:1
  • 9Russell GFJ.Starch microspheres as drug delivery system.Pharmacy International.1983; (10):260. 被引量:1
  • 10Lindberg B,Lote K,Teder H,et al.Microspheres and drug therapy pharmaceutical immunological and medical aspects 1984.Elsevier Science Publishers BU.1984:153. 被引量:1

共引文献26

同被引文献18

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部